Research
Hormonal
GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.
Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.
StrongSupportsmedium confidence
Für diesen Wirkstoff ist auch nachgewiesen, dass er kardiovaskuläre Ereignisse verhindern kann.
Why this rating
Die Aussage basiert auf nachgewiesenen Wirkungen des Medikaments.
Source
GLP-1-Rezeptoragonisten bei Übergewicht
Stefan Weiler et al. · pharma-kritik · 2026
DOI 10.37667/pk.2026.1450
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →